ADC Therapeutics SA (ADCT) Reports Q2 Loss, Lags Revenue Estimates

Company Performance - ADC Therapeutics reported a quarterly loss of $0.38 per share, better than the Zacks Consensus Estimate of a loss of $0.44, and an improvement from a loss of $0.58 per share a year ago [1] - The company posted revenues of $17.41 million for the quarter, missing the Zacks Consensus Estimate by 8.63%, and down from $19.28 million year-over-year [1] - Over the last four quarters, ADC Therapeutics has surpassed consensus EPS estimates two times and topped revenue estimates just once [1] Stock Movement and Outlook - ADC Therapeutics shares have increased by approximately 72.9% since the beginning of the year, significantly outperforming the S&P 500's gain of 8.7% [2] - The sustainability of the stock's price movement will depend on management's commentary during the earnings call and future earnings expectations [2][3] Earnings Estimates and Industry Context - The current consensus EPS estimate for the upcoming quarter is -$0.41 on revenues of $20.06 million, and for the current fiscal year, it is -$1.87 on revenues of $78.17 million [4] - The Zacks Industry Rank for Medical - Biomedical and Genetics is in the top 37% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [5] - VistaGen Therapeutics, another company in the same industry, is expected to report a quarterly loss of $0.41 per share, reflecting a year-over-year change of +56.4%, with revenues expected to be $0.3 million, up 66.7% from the previous year [5]